10.1038/5030 Nat
The weight loss effect of 14 mg oral semaglutide appears numerically comparable to older obesity treatments: orlistat (360 mg daily) with 8% weight loss and 51% achieving at least 5% weight loss, naltrexone-bupropion (32/360 mg) with 6% weight loss and with 48% achieving at least 5% weight loss and liraglutide (3 mg daily) with 8 kg weight loss and 63% achieving at least 5% weight loss ( The retrospective and observational design of our study facilitated faster execution, however, several limitations must be acknowledged
Your physician monitors your response throughout and will adjust dosing if needed
The generic drug approval process requires companies to demonstrate that their products contain the same active ingredients and deliver the same therapeutic effects as the original brand-name medication
Actual costs may be lower with private insurance, Medicare, or savings programs, if prescribed for diabetes, heart, or kidney conditions
however, uncertainty persists due to heterogeneity in study design, outcome definitions, and follow-up duration